

SUPPLEMENTARY DATA

SELF-ASSEMBLING HUMAN HEART ORGANOIDS FOR THE MODELING OF CARDIAC DEVELOPMENT AND CONGENITAL HEART DISEASE

Yonatan R. Lewis Israeli^{1,2}, Aaron H. Wasserman^{1,2}, Mitchell Gabalski^{1,2}, Kristen Ball^{1,2}, Brett Volmert^{1,2}, Weiyang Yang^{3,4}, Bo Li^{2,3}, Jinyun Zou⁶, Guangming Ni⁶, Natalia Pajares⁵, Xanthippi Chatzistavrou⁵, Chao Zhou⁶, Zhen Qiu^{2,3}, Wen Li^{3,4} and Aitor Aguirre^{1,2*}

¹Institute for Quantitative Health Science and Engineering, Division of Developmental and Stem Cell Biology, Michigan State University, MI, USA

²Department of Biomedical Engineering, College of Engineering, Michigan State University, MI, USA



³Institute for Quantitative Health Science and Engineering, Division of Biomedical Devices, Michigan State University, MI, USA

⁴Department of Electrical and Computer Engineering, College of Engineering, Michigan State University, MI, USA


⁵Department of Chemical Engineering and Material Science, College of Engineering, Michigan State University, MI, USA

⁶Department of Biomedical Engineering, Washington University at Saint Louis, MO, USA


*Corresponding author (email: aaguirre@msu.edu)




Supplementary Figure 1. **a**, Confocal immunofluorescent images for DAPI (blue) and TNNT2 (red), in organoids with CHIR99021 exposure concentrations of 4 μ M (top), 6.6 μ M (middle), and 8 μ M (bottom) at day 15. Scale bars, 500 μ m. **b**, Frequency of beats per minute of the hHOs and **c**, percentage of beating hHOs per treatment. (Value = mean \pm s.d., 1-way ANOVA multiple comparison test; **p<0.01, ***p<0.0001).




Supplementary Figure 2. **a**, Confocal immunofluorescent images for DAPI (blue) and TNNT2 (red), in hHOs showing epicardial markers ALDH2A (green) and TJP1 (white) near edge of the organoid. **b**, Area analysis of cardiomyocyte regions (TNNT2+) and epicardial regions (WT1+ and TJP1+) within organoids taken at multiple z-planes as a percentage of DAPI+ regions of each organoid treated with CHIR99021 at day 7 for different time durations, and **c**, representative confocal immunofluorescent images of organoids from these time durations: Scale bar: 500 μ m. (Value = mean \pm s.d., 1-way ANOVA multiple comparison test; *p<0.05).








Supplementary Figure 3.a, Gene expression analysis indicating of more first and second heart field markers over heart organoid differentiation process. **b**, Gene expression analysis (\log_2 fold-change vs. D0) for cardiac-specific cell type populations in heart organoids, including (from top left to bottom right) endocardial cells, epicardial cells, endothelium and cardiac fibroblasts. **c**, Gene expression analysis (\log_2 fold-change vs. D0) for cardiomyocyte markers. **d**, Gene expression analysis (\log_2 fold-change vs. D0) for ECM protein coding genes that are present in cardiac tissue. **e**, Principal component analysis of heart organoid differentiation over time.




Supplementary Figure 4. **a**, 3D reconstruction of OCT images and **b**, bright field image of hHO. **c**, OCT images showing cross-section of center of 9 different organoids, revealing central chambers; scale bar: 500 μ m. **d**, Immunofluorescence images of organoids derived from a flipGFP transgenic iPSC line L1 showing no apoptosis in control hHOs (left) and high apoptosis in hHOs treated with 5 μ M Doxorubicin (DOX) (right); scale bar: 500 μ m.



Supplementary Figure 5. Microelectrode array (MEA) recording system showing the gold electrode array in a PDMS chamber where the organoid is placed within a Faraday cage inside an incubator.

a**b****d****e**

Supplementary Figure 6. Human heart organoids modeling functional features healthy vs diabetic conditions. **a**, Schematic of heart tube formation and looping into the four chambers of the heart. **b**, Representative MEA electrophysiology detail of normal vs. diabetic organoids. **c**, Amplitude magnitude in μ V of action potentials in normal and diabetic hHOs ($n > 12$ over 3 replicates per condition; unpaired t-test, $***p < 0.001$). **d**, Beating frequency in beats per minute (BPM) in normal and diabetic organoids as recorded by MEA (mean \pm SD, $n > 5$ organoids; unpaired t-test, $*p < 0.05$.) **e**, Seahorse energy map of normal and diabetic-like organoids (mean \pm sd).



Supplementary Figure 7. Illustration of a custom SD-OCT imaging system, FC: fiber coupler, PC: polarization controller, C1-C3: collimator, L1 - L4: lens, GS: galvo scanner; G: grating.

	Antibody name	Host Species	Dilution	Vendor
Primary	cTnT	Mouse	1:200	Abcam
	WT1	Rabbit	1:200	Abcam
	ZO1	Goat	1:250	Thermo Fisher Scientific
	ALDH1A2	Rabbit	1:200	Abcam
	Vimentin	Goat	1:200	Abcam
	CD90/Thy1	Rabbit	1:200	Abcam
	NFAT2	Rabbit	1:100	Abcam
	CD31	Rabbit	1:50	Abcam
Secondary	Alexa Fluor 488	Donkey anti-mouse	1:200	Thermo Fisher Scientific
	Alexa Fluor 488	Donkey anti-rabbit	1:200	Thermo Fisher Scientific
	Alexa Fluor 594	Donkey anti-mouse	1:200	Thermo Fisher Scientific
	Alexa Fluor 594	Donkey anti-rabbit	1:200	Thermo Fisher Scientific
	Alexa Fluor 647	Donkey anti-goat	1:200	Thermo Fisher Scientific

Supplementary Table 2. Antibodies used for immunofluorescence in this report.